The role of concurrent amplification of PD-L1, PD-L2 and JAK2 in metastatic lung adenocarcinoma as a biomarker of immune checkpoint inhibitor response: a case report

Abstract

Background: Immune checkpoint inhibitors (ICIs) have transformed the landscape of care for many malignancies, including non-small cell lung cancer (NSCLC). That said, ICIs are associated with significant immune related adverse events (IrAE) and most patients do not benefit. As a result, significant efforts have been devoted to identifying biomarkers able to predict response to ICIs.